1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Center Laboratories, Inc.

Center Laboratories, Inc.

TTPEX:4123
29.90
TWD
0.00
(0.00%)
1.20EPS
28.17P/E
28.77BMarket Cap
Center Laboratories, Inc.
TPEX:4123
(Taipei Exchange)

Recent

price

29.90

P/E

ratio

28.17

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
2.03
2.27
1.89
1.74
1.87
12.56
24.9
42.05
34.68
2.22
1.05
0.71
1.08
1.9
2.07
1.91
2.1
Revenue per Share
0.05
0.14
0.24
0.12
0.69
0.78
0.03
0.54
9.75
-0.44
5.55
2.59
0.14
-1.36
-1.41
11.75
1.29
Basic EPS, GAAP
-0.17
-0.62
-0.38
-0.18
-0.21
-1.07
-0.83
-2.12
-2.14
-1.4
-0.5
-0.52
-0.28
-1.55
0.28
-0.23
0.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.19
0.39
2.41
0.82
0.91
1.5
2.46
0.81
1.32
0.68
- -
Dividend per Share
5.27
5.79
6.58
7.79
9.92
11.21
11.19
11.19
20.43
20.02
25.64
26.93
26.64
26.11
22.72
33.79
21.69
Book Value per Share
5.09
5.67
6.47
7.71
9.85
1.31
1.59
0.7
20.4
19.99
25.63
26.92
26.63
25.01
21.74
32.86
20.79
Tangible Book Value per Share
281
301
378
427
481
541
604
461
624
648
682
702
711
732
783
794
789
Basic Weighted Avg Shares
569
684
714
742
899
6,792
15,040
19,392
21,648
1,438
717
500
768
1,394
1,618
1,516
1,657
Sales/Revenue/Turnover
-3.92
0.64
-5.75
-5.37
-7.73
-0.69
2.86
4.58
6.01
-6.2
-65.94
-50.82
37.05
5.63
14.48
-23.88
3.34
Operating Margin (%)
42
47
52
62
63
324
800
873
923
119
57
35
33
148
161
173
180
Depreciation Expense
13
43
92
52
333
422
19
250
6,084
-286
3,786
1,816
102
-995
-1,104
9,323
1,019
Net Income, GAAP
- -
42.92
33.79
23.45
18.27
23.5
58.71
42.44
19.37
301.9
18.52
16.9
- -
- -
- -
19.41
37.58
Effective Tax Rate (%)
2.28
6.22
12.93
7
37.08
6.21
0.13
1.29
28.1
-19.92
528.07
363.16
13.31
-71.41
-68.22
614.89
61.51
Profit Margin (%)
1,420
1,433
2,106
3,316
1,138
6,684
3,502
532
715
-2,718
-1,322
8,213
-1,072
3,276
-835
-1,920
2,029
Working Capital
- -
93
- -
- -
- -
4,700
2,675
3,840
2,183
1,610
1,778
3,676
1,289
4,429
2,663
1,774
3,745
LT Debt
2,183
2,561
3,460
5,013
6,936
14,884
15,823
16,869
15,467
15,458
20,634
21,095
19,252
20,216
18,054
26,487
17,156
Total Equity
- -
0.09
-0.82
-0.81
-0.79
-0.21
0.72
1.86
4.26
0.96
-1.76
-0.82
- -
- -
- -
-1.04
0.16
Return on Invested Capital (%)
- -
3.07
4.23
0.87
2.73
3.38
-0.52
-0.76
18.75
-3.15
12.73
6.15
- -
- -
- -
34.02
5.18
Return on Capital (%)
0.8
2.44
4.43
1.72
7.44
7.11
0.29
3.68
61.24
-2.17
24.23
9.84
0.54
-5.1
-5.84
41.86
6
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,930
4,360
356
LT Borrowings
1,774
639
3,743
LT Finance Leases
- -
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
784
784
791
Market Capitalization
31,083
30,261
28,768

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,590
4,819
4,425
Cash, Cash Equivalents & STI
974
4,189
3,846
Accounts Receivable, Net
214
249
235
Inventories
353
328
305
Total Current Liabilities
3,510
5,168
2,396
Payables & Accruals
- -
- -
- -
ST Debt
2,930
4,360
356
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.25%
6.9%
46.7%
Free Cash Flow
15.65%
26.6%
-183.72%
Net Income, GAAP
-25.77%
-430.81%
-944.7%
Sales/Revenue/Turnover
13.31%
22.92%
-6.28%
Total Cash Common Dividend
- -
19.17%
-47.58%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
363
413
392
449
1,618
2025
379
379
359
400
1,516
2026
466
432
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.71
-0.09
0.34
-0.96
-1.41
2025
0.69
-0.91
3.44
8.65
11.75
2026
2.49
-13.12
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.32
2025
- -
- -
- -
- -
0.68
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Center Laboratories, Inc. (4123.TWO) operates as a biotechnology venture holdings group that develops, manufactures, and markets pharmaceuticals while investing in and incubating biotech firms across Asia Pacific. The company offers general medication pharmaceuticals, including antipyretic and analgesic agents, bronchodilators, anti-inflammatory preparations, anti-allergic agents, expectorants, narcotic and non-narcotic antitussives, gastrointestinal preparations, and other medicines; central nervous system medications for cerebrovascular disease, dementia, depression, schizophrenia, epilepsy, and Parkinson's disease; diabetes treatments targeting pancreatic beta cells; and specialty oral liquid formulations for infants, children, the elderly, and special care patients, holding a dominant 70% share of Taiwan's oral liquid drug market. It also engages in biotechnology investments, drug development, cell therapy, biopharmaceuticals, hydrogen energy, and dairy-related businesses through subsidiaries and portfolio companies. Center Laboratories maintains operations primarily in Taiwan with international reach in pharmaceuticals sales and biotech investments spanning China, Hong Kong, and Asia Pacific markets, targeting healthcare providers, patients, and biotech innovators. Founded in 1959 and headquartered in Taipei City, Taiwan, the company has undergone strategic transformations: in 1998 repositioning as a professional oral liquid pharmaceutical firm; in 2008 as a "Biotechnology Industrial Bank" via subsidiaries Bioengine Capital Inc. and Bioengine Technology Development Inc.; and in 2018 as the Center Ventures Group, a professional biotech venture holdings platform focused on operational revamps, mergers, acquisitions, and unicorn incubation exceeding NTD30 billion market caps. Recent developments include the 2022 full acquisition of Bioengine Technology Development Inc. and merger with Bioengine Capital Inc. to bolster venture capital positioning; 2023 investments in green hydrogen firm UMOE and Krisan Biotech for ADC CDMO services alongside Mycenax Biotech; 2024 board resolution for up to NTD10 billion purchase of investee Shuntian Pharmaceuticals (6535.TT) shares at NTD150-225 per share; and 2025 joint venture formation by portfolio company Ever Supreme Bio (Yongxin) with Japan's Alfresa-led firms for Alfenax Biologic Corporation, alongside strong portfolio performances from investees like Kacose Pharma and Shanghai Baoji Pharma. These moves underscore dual growth engines in core pharmaceuticals and emergent biotech investments, with Q3 2025 earnings reflecting NT$30.67 billion in financial asset gains and front-nine-month EPS of NT$3.52.